Of the 15 patients with PIK3CA mutations, none demonstrated an objective tumor response to EGFR inhibitor therapy, and an overall trend of decreased PFS was observed.
1
—
—
Of the 15 patients with PIK3CA mutations, none demonstrated an objective tumor response to EGFR inhibitor therapy, and an overall trend of decreased PFS was observed.